AKB-9778:
A Paradigm Shift

in the treatment of diabetic eye disease

Learn more...

World of Indications

New Approach for IBD

Orally-administered, once-daily AKB-4924 is the only drug candidate in development that directly addresses both inflammation and mucosal wound healing.

Learn more...

IBD Pill
Tie 2 Symposium
About

Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.

Our lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor 1-α (HIF-1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, phase 2a study (TIME-2). AKB-4924, the lead compound in our and the HIF-1-α stabilization program, has recently completed a Phase 1a study.

Learn more...
Pipeline
Aerpio Pipeline
News

6/13/16 - Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Read the press release.

11/17/15 - Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Read the press release.

10/9/15 - Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

Read the press release.